ROLE OF TNF AND IL-1 IN PATHOPHYSIOLOGY AND HOST-DEFENCE MECHANISM IN PATIETNTS WITH PROSTATE CANCER

TNF 和 IL-1 在前列腺癌患者病理生理学和宿主防御机制中的作用

• 批准号: 06671615
• 负责人: HORIGUCHI Yutaka
• 金额: $ 1.41万
• 依托单位: KEIO UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 1996
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-06671615/
• 关键词: PROSTATE CANCER; TUMOR NECROSIS FACTOR; COAGULOPATHY; CACHEXIA; TNF

The present study was undertaken to evaluate the relationship between serum tumor necrosis factor (TNF) and coagulopathy and cachexia in patients with prostate cancer. TNF levels were determined in 110 serum samples from prostate cancer patients by an enzyme immunoassay. Serum TNF activity was positive in 76% of the patients with relapsed disease, whereas only 11% of the untreated patients and 0% of the patients in remission as a result of endocrine therapy were positive. Serum levels of fibrin/fibrinogen degradation product E fragment (FDP) and plasma levels of fibrin degradation product D-dimer (D-dimer), thrombin-antithrombin-III complex (TAT) and plasmin-a2-antiplasmin inhibitor complex (PIC) in patients with elevated serum TNF levels were significantly higher than those in patients with undetectable serum TNF levels. Patients with coagulopathy had a significant increase in serum TNF levels. The serum total protein and albumin levels, hemoglobin levels, and body mass index and performance status of the patients with elevated serum TNF levels were significantly impaired than the corresponding values in patients with undetectable serum TNF levels. Patients with elevated serum TNF levels had a significantly higher mortality rate than those with undetectable serum TNF levels. Patients with cachexia showed a significant increase in serum TNF levels than patients without cachexia. These findings suggest that TNF may be one of the factors contributing to the coagulopathy and complex syndrome of cachexia in patients with prostate cancer.

本研究旨在探讨前列腺癌患者血清肿瘤坏死因子(TNF)与凝血障碍和恶病质的关系。用酶免疫法测定了110例前列腺癌患者血清中肿瘤坏死因子的水平。复发组血清肿瘤坏死因子活性阳性率为76%，而初治组和内分泌治疗缓解组阳性率分别为11%和0%。血清肿瘤坏死因子水平升高患者血清纤维蛋白/纤维蛋白原降解产物E片段(FDP)和血浆纤维蛋白降解产物D-二聚体(D-二聚体)、凝血酶-抗凝血酶-III复合体(TAT)和纤溶酶-α2-抗纤溶酶抑制物复合体(PIC)水平显著高于血清肿瘤坏死因子水平阴性患者。凝血障碍患者血清肿瘤坏死因子水平明显升高。血清肿瘤坏死因子水平升高患者的血清总蛋白和白蛋白水平、血红蛋白水平、体重指数和运动状态明显低于未检测到血清肿瘤坏死因子水平患者的相应数值。血清肿瘤坏死因子水平升高的患者死亡率显著高于血清肿瘤坏死因子水平未检测到的患者。恶病质患者血清肿瘤坏死因子水平明显高于无恶病质患者。提示肿瘤坏死因子可能是前列腺癌患者出现凝血障碍和恶病质复杂综合征的因素之一。

项目成果

Jun Nakashima et al.: "Tumor necosis factor and coagulopathy inpatients with prostate cancer" Cancer Research. 55. 4881-4885 (1995)

Jun Nakashima 等人：“前列腺癌住院患者的肿瘤坏死因子和凝血障碍”癌症研究。

Jun Nakashima et al.: "Tumor necrosis factor and coajulopathy in patients with prostate cancer" Cancer Research. 55. 4881-4885 (1995)

Jun Nakashima 等人：“前列腺癌患者的肿瘤坏死因子和凝血病”癌症研究。

Jun Nakashima, et al.: "Tumor necrosis factor and coagulopathy in patients with prostate cancer." Cancer Research. 55. 4881-4885 (1995)

Jun Nakashima 等人：“前列腺癌患者的肿瘤坏死因子和凝血障碍。”